Patients diagnosed with gMG who are expected to start commercial efgartigimod at enrolment or who are within their first cycle of efgartigimod at enrolment or Patients diagnosed with gMG who have not been exposed to efgartigimod and for whom it is not planned to start treatment with efgartigimod at enrolment
Have provided appropriate written informed consent
You may not be if
None
Clareo Health | A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
